Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225275280> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4225275280 endingPage "e198" @default.
- W4225275280 startingPage "e198" @default.
- W4225275280 abstract "The International Kidney Cancer Coalition, representing 1·2 million patients with kidney cancer globally, and its medical advisory board commend the comprehensive analysis by David Cella and colleagues 1 Cella D Motzer RJ Suarez C et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23: 292-303 Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar of patient-reported outcomes (PROs) and quality of life (QOL) among patients diagnosed with metastatic renal cell carcinoma that was published in The Lancet Oncology. However, the patient community would like to raise a few additional points of discussion. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trialPROs were maintained or improved with nivolumab plus cabozantinib versus sunitinib. Compared with sunitinib, nivolumab plus cabozantinib significantly delayed time to deterioration of patient-reported outcome scores. These results suggest a benefit for nivolumab plus cabozantinib compared with sunitinib in the treatment of patients with advanced renal cell carcinoma. Full-Text PDF Patient-reported outcomes: what really matters to patients? – Authors' replyWe very much appreciate Elshad Hasanov and colleagues' interest in our Article1 and the input from the international community of patients with kidney cancer. We involve the patient community when designing patient-reported outcome (PRO) measures. The points raised by Hasanov and colleagues are important to bear in mind when planning to evaluate new drug treatments for advanced kidney cancer. Late effects of new treatments, including immune checkpoint inhibitors, are important to monitor, particularly when considering long-term benefit. Full-Text PDF" @default.
- W4225275280 created "2022-05-04" @default.
- W4225275280 creator A5005273084 @default.
- W4225275280 creator A5009171545 @default.
- W4225275280 creator A5011578307 @default.
- W4225275280 creator A5024327224 @default.
- W4225275280 creator A5085368277 @default.
- W4225275280 date "2022-05-01" @default.
- W4225275280 modified "2023-10-18" @default.
- W4225275280 title "Patient-reported outcomes: what really matters to patients?" @default.
- W4225275280 cites W3009804007 @default.
- W4225275280 cites W3014549147 @default.
- W4225275280 cites W4205479620 @default.
- W4225275280 cites W4206186024 @default.
- W4225275280 cites W4210806725 @default.
- W4225275280 doi "https://doi.org/10.1016/s1470-2045(22)00156-5" @default.
- W4225275280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35489342" @default.
- W4225275280 hasPublicationYear "2022" @default.
- W4225275280 type Work @default.
- W4225275280 citedByCount "1" @default.
- W4225275280 countsByYear W42252752802023 @default.
- W4225275280 crossrefType "journal-article" @default.
- W4225275280 hasAuthorship W4225275280A5005273084 @default.
- W4225275280 hasAuthorship W4225275280A5009171545 @default.
- W4225275280 hasAuthorship W4225275280A5011578307 @default.
- W4225275280 hasAuthorship W4225275280A5024327224 @default.
- W4225275280 hasAuthorship W4225275280A5085368277 @default.
- W4225275280 hasConcept C121608353 @default.
- W4225275280 hasConcept C126322002 @default.
- W4225275280 hasConcept C143998085 @default.
- W4225275280 hasConcept C2777472916 @default.
- W4225275280 hasConcept C2777701055 @default.
- W4225275280 hasConcept C2779490328 @default.
- W4225275280 hasConcept C2780030458 @default.
- W4225275280 hasConcept C2781064419 @default.
- W4225275280 hasConcept C2781068499 @default.
- W4225275280 hasConcept C71924100 @default.
- W4225275280 hasConceptScore W4225275280C121608353 @default.
- W4225275280 hasConceptScore W4225275280C126322002 @default.
- W4225275280 hasConceptScore W4225275280C143998085 @default.
- W4225275280 hasConceptScore W4225275280C2777472916 @default.
- W4225275280 hasConceptScore W4225275280C2777701055 @default.
- W4225275280 hasConceptScore W4225275280C2779490328 @default.
- W4225275280 hasConceptScore W4225275280C2780030458 @default.
- W4225275280 hasConceptScore W4225275280C2781064419 @default.
- W4225275280 hasConceptScore W4225275280C2781068499 @default.
- W4225275280 hasConceptScore W4225275280C71924100 @default.
- W4225275280 hasIssue "5" @default.
- W4225275280 hasLocation W42252752801 @default.
- W4225275280 hasLocation W42252752802 @default.
- W4225275280 hasOpenAccess W4225275280 @default.
- W4225275280 hasPrimaryLocation W42252752801 @default.
- W4225275280 hasRelatedWork W2804329561 @default.
- W4225275280 hasRelatedWork W2891290712 @default.
- W4225275280 hasRelatedWork W3134949580 @default.
- W4225275280 hasRelatedWork W3161601890 @default.
- W4225275280 hasRelatedWork W4212986922 @default.
- W4225275280 hasRelatedWork W4213376619 @default.
- W4225275280 hasRelatedWork W4225275280 @default.
- W4225275280 hasRelatedWork W4282567532 @default.
- W4225275280 hasRelatedWork W4285598862 @default.
- W4225275280 hasRelatedWork W4362587156 @default.
- W4225275280 hasVolume "23" @default.
- W4225275280 isParatext "false" @default.
- W4225275280 isRetracted "false" @default.
- W4225275280 workType "article" @default.